Drug makers continue to face more securities fraud lawsuits

first_img Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED GET STARTED Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. About the Author Reprints Drug makers continue to face more securities fraud lawsuits Ed Silverman STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @Pharmalot What’s included? Shareholders regularly file lawsuits seeking class-action status against companies alleging securities fraud. But the life sciences industry continues to attract more than others, according to a new analysis.Last year, there were 67 such lawsuits filed against drug makers and biotechs, along with their directors, officers, and key personnel. This amounted to a whopping 71 percent increase from 2015 and was also substantially higher than at any time in the past five years, according to the Dechert law firm, which conducted the analysis.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ed Silverman March 2, 2017 Reprints Log In | Learn More APStock [email protected] Pharmalot What is it? Tags LitigationpharmaceuticalsSTAT+last_img read more